Clinical Biomarker Discovery Initiative would speed progress in early detection and measurement of response to therapy, Leland Hartwell tells NCI.
Also in this 8-page issue: Dept. of Justice, Congress to investigate Merck and FDA actions on Vioxx; FDA asks IOM to study its monitoring system for approved drugs.
NCI appoints Robert Young chairman of the Board of Scientific Advisors, reappoints Ellen Sigal, and names 11 new members to board. Earnest Hawk to direct NCI Office of Centers, Training and Resources.
St. Jude Children’s wins NCI contract for Pediatric Preclinical Testing Program.
Funding opportunities listed.
Trending Stories
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research









